A tumor-specific modulation of heterogeneous ribonucleoprotein A0 promotes excessive mitosis and growth in colorectal cancer cells.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
17 04 2020
17 04 2020
Historique:
received:
31
05
2019
accepted:
10
12
2019
revised:
10
12
2019
entrez:
19
4
2020
pubmed:
19
4
2020
medline:
1
4
2021
Statut:
epublish
Résumé
RNA regulation mediating RNA-binding proteins (RBPs) have been shown to be related to the maintenance of homeostasis as well as cancer progression. However, the tumor-associated functions as well as the detailed mechanisms underlying the anti-tumor effects of most RBPs have yet to be explored. We herein report that the phosphorylated heterogeneous ribonucleoprotein (hnRNP) A0 promotes mitosis through the RAS-associated protein 3 GTPase-activating protein catalytic subunit 1 (RAB3GAP1)-Zeste white 10 interactor (ZWINT1) cascade. The downregulation assay of 20 representative hnRNPs, a major family of RNA-binding proteins, in colorectal cancer cells revealed that hnRNPA0 is a strong regulator of cancer cell growth. The tumor promotive function of hnRNPA0 was confirmed in gastrointestinal cancer cells, including pancreatic, esophageal, and gastric cancer cells, but not in non-cancerous cells. Flow cytometry and Western blotting analyses revealed that hnRNPA0 inhibited the apoptosis through the maintenance of G2/M phase promotion in colorectal cancer cells. A comprehensive analysis of mRNAs regulated by hnRNP A0 and immunostaining revealed that mitotic events were regulated by the hnRNPA0-RAB3GAP1 mRNA-mediated ZWINT-1 stabilization in colorectal cancer cells, but not in non-tumorous cells. The interaction of hnRNP A0 with mRNAs was dramatically changed by the deactivation of its phosphorylation site in cancer cells, but not in non-tumorous cells. Therefore, the tumor-specific biological functions characterized by the abnormal phosphorylation of RBPs are considered to be an attractive target for tumor treatment.
Identifiants
pubmed: 32303675
doi: 10.1038/s41419-020-2439-7
pii: 10.1038/s41419-020-2439-7
pmc: PMC7165183
doi:
Substances chimiques
Ribonucleoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Références
Fitzmaurice, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 4, 1553–1568 (2018).
doi: 10.1001/jamaoncol.2018.2706
Nilsen, T. W. & Graveley, B. R. Expansion of the eukaryotic proteome by alternative splicing. Nature 463, 457–463 (2010).
doi: 10.1038/nature08909
Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17–37 (2013).
pubmed: 23540688
pmcid: 23540688
Schmitt, A. M. & Chang, H. Y. Long noncoding RNAs in cancer pathways. Cancer Cell 29, 452–463 (2016).
doi: 10.1016/j.ccell.2016.03.010
Grammatikakis, I. et al. Alternative splicing of neuronal differentiation factor TRF2 regulated by HNRNPH1/H2. Cell Rep. 15, 926–934 (2016).
doi: 10.1016/j.celrep.2016.03.080
Fujiya, M. et al. microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1. Oncogene 33, 4847–4856 (2014).
doi: 10.1038/onc.2013.429
Konishi, H. et al. microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA. Biochem. Biophys. Res. Commun. 467, 847–852 (2015).
doi: 10.1016/j.bbrc.2015.10.055
Tauler, J., Zudaire, E., Liu, H., Shih, J. & Mulshine, J. L. hnRNP A2/B1 modulates epithelial–mesenchymal transition in lung cancer cell lines. Cancer Res. 70, 7137–7147 (2010).
doi: 10.1158/0008-5472.CAN-10-0860
Uren, P. J. et al. High-throughput analyses of hnRNP H1 dissects its multi-functional aspect. RNA Biol. 13, 400–411 (2016).
doi: 10.1080/15476286.2015.1138030
Liu, T. Y. et al. Muscle developmental defects in heterogeneous nuclear ribonucleoprotein A1 knockout mice. Open Biol. 7, pii:160303 (2017).
Ye, J. et al. hnRNP U protein is required for normal pre-mRNA splicing and postnatal heart development and function. Proc. Natl Acad. Sci. USA 112, E3020–E3029 (2015).
doi: 10.1073/pnas.1508461112
Gueroussov, S. et al. Regulatory expansion in mammals of multivalent hnRNP assemblies that globally control alternative splicing. Cell 170, 324–339.e23 (2017).
doi: 10.1016/j.cell.2017.06.037
Geuens, T., Bouhy, D. & Timmerman, V. The hnRNP family: insights into their role in health and disease. Hum. Genet. 135, 851–867 (2016).
doi: 10.1007/s00439-016-1683-5
Wang, Z. N. et al. High expression of PTBP1 promote invasion of colorectal cancer by alternative splicing of cortactin. Oncotarget 8, 36185–36202 (2017).
pubmed: 28404950
pmcid: 5482648
Dreyfuss, G., Kim, V. N. & Kataoka, N. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol 3, 195–205 (2002).
doi: 10.1038/nrm760
David, C. J., Chen, M., Assanah, M., Canoll, P. & Manley, J. L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364–368 (2010).
doi: 10.1038/nature08697
Chaudhury, A. et al. TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat. Cell Biol. 12, 286–293 (2010).
doi: 10.1038/ncb2029
Jo, O. D. et al. Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling. J. Biol. Chem. 283, 23274–23287 (2008).
doi: 10.1074/jbc.M801185200
Barceló, C. et al. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Gastroenterology 147, 882–892.e8 (2014).
doi: 10.1053/j.gastro.2014.06.041
Li, X. et al. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat. Cell Biol. 18, 561–571 (2016).
doi: 10.1038/ncb3338
Gallardo, M. et al. hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies. Cancer Cell 28, 486–499 (2015).
doi: 10.1016/j.ccell.2015.09.001
Dreyfuss, G., Matunis, M. J., Pinol-Roma, S. & Burd, C. G. hnRNP proteins and the biogenesis of mRNA. Annu. Rev. Biochem. 62, 289–321 (1993).
doi: 10.1146/annurev.bi.62.070193.001445
Löbrich, M. & Jeggo, P. A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat. Rev. Cancer 7, 861–869 (2007).
doi: 10.1038/nrc2248
Rousseau, S. et al. Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J. 21, 6505–6514 (2002).
doi: 10.1093/emboj/cdf639
Musacchio, A. & Salmon, E. D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 8, 379–393 (2007).
doi: 10.1038/nrm2163
van Leuken, R., Clijsters, L. & Wolthuis, R. To cell cycle, swing the APC/C. Biochim. Biophys. Acta 1786, 49–59 (2008).
pubmed: 18544349
Hagting, A. et al. Human securin proteolysis is controlled by the spindle checkpoint and reveals when the APC/C switches from activation by Cdc20 to Cdh1. J. Cell Biol. 157, 1125–1137 (2002).
doi: 10.1083/jcb.200111001
Clute, P. & Pines, J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat. Cell Biol. 1, 82–87 (1999).
doi: 10.1038/10049
Woo Seo, D. et al. Zwint-1 is required for spindle assembly checkpoint function and kinetochore–microtubule attachment during oocyte meiosis. Sci. Rep. 5, 15431 (2015).
doi: 10.1038/srep15431
Famulski, J. K., Vos, L., Sun, X. & Chan, G. Stable hZW10 kinetochore residency, mediated by hZwint-1 interaction, is essential for the mitotic checkpoint. J. Cell Biol. 180, 507–520 (2008).
doi: 10.1083/jcb.200708021
Obuse, C. et al. A conserved Mis12 centromere complex is linked to heterochromatic HP1 and outer kinetochore protein Zwint-1. Nat. Cell Biol. 6, 1135–1141 (2004).
doi: 10.1038/ncb1187
Peng, F. et al. ZWINT is the next potential target for lung cancer therapy. J. Cancer Res. Clin. Oncol. 145, 661–673 (2019).
doi: 10.1007/s00432-018-2823-1
Ying, H. et al. Overexpression of Zwint predicts poor prognosis and promotes the proliferation of hepatocellular carcinoma by regulating cell-cycle-related proteins. Onco Targets Ther. 11, 689–702 (2018).
doi: 10.2147/OTT.S152138
Endo, H., Ikeda, K., Urano, T., Horie-Inoue, K. & Inoue, S. Terf/TRIM17 stimulates degradation of kinetochore protein ZWINT and regulates cell proliferation. J. Biochem. 151, 139–144 (2012).
doi: 10.1093/jb/mvr128
Fukuda, M. TBC proteins: GAPs for mammalian small GTPase Rab? Biosci. Rep. 31, 159–168 (2011).
doi: 10.1042/BSR20100112
van Vlijmen, T. et al. A unique residue in rab3c determines the interaction with novel binding protein Zwint-1. FEBS Lett. 582, 2838–2842 (2008).
doi: 10.1016/j.febslet.2008.07.012
Fukuda, M. Regulation of secretory vesicle traffic by Rab small GTPases. Cell Mol. Life Sci. 65, 2801–2813 (2008).
doi: 10.1007/s00018-008-8351-4
Conner, S. D. & Wessel, G. M. A rab3 homolog in sea urchin functions in cell division. FASEB J. 14, 1559–1566 (2000).
doi: 10.1096/fj.99-0812com